U.S. Senator Seeks FDA Probe Of Bulk Drug Outsourcing
This article was originally published in PharmAsia News
A U.S. senator is urging the FDA to take a closer look at producers of bulk drugs based in China and India. Sen. Sherrod Brown, D-Mich., said in a letter to Janet Woodcock, director of the Center for Drug Evaluation & Research, the agency should look into the trend of outsourcing pharmaceutical ingredients. In a separate letter, Brown, a member of a Senate drug oversight committee, also asked Pfizer to provide details of its own practice of outsourcing work to countries that lack the U.S. level of standards for drug safety. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.